Carl Zeiss Meditec
€31.30Change from previous close: +0.32%Absolute change: +€0.10
At a glance
- Revenue growth
- +7.82%
- FY to Sep 2025 vs FY to Sep 2024
- Net income growth
- −20.99%
- FY to Sep 2025 vs FY to Sep 2024
- Net margin
- 6.3%
- FY to Sep 2024: 8.7%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | FY to Sep 2025 | FY to Sep 2024 | FY to Sep 2023 | FY to Sep 2022 |
|---|---|---|---|---|
| Operating cash flow | 210 | 247 | 251 | 188 |
| Depreciation and amortization | 126 | 133 | 74.1 | 69.8 |
| Capital expenditure | -76.6 | -152 | -114 | -82.0 |
| Investing cash flow | -91.0 | -412 | -111 | -92.9 |
| Financing cash flow | -109 | 176 | -135 | -94.2 |
| Dividends paid | -52.5 | -98.2 | -98.4 | -80.5 |
| Share repurchases | 0.0 | -150 | 0.0 | — |
| Debt issued | 0.0 | 400 | 0.0 | — |
| Debt repaid | — | — | 0.0 | -1.5 |
| Effect of exchange rates | -3.0 | -1.6 | -1.9 | -0.8 |
| Net change in cash | 10.0 | 11.3 | 4.8 | 1.1 |
| Free cash flow | 133 | 95.1 | 137 | 106 |